Literature DB >> 1976051

The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma.

H H Windom1, C D Burgess, R W Siebers, G Purdie, N Pearce, J Crane, R Beasley.   

Abstract

The cardiovascular, respiratory, and hypokalemic effects of repeated inhalation of fenoterol, albuterol, and isoproterenol were compared in 12 subjects with stable asthma according to a double-blind, crossover design. Ipratropium bromide served as a control providing bronchodilatation without extrapulmonary effects. Subjects inhaled the beta-agonists on an equal-weight basis (400 micrograms) at 0, 30, 40, and 45 minutes. Measurements of heart rate, blood pressure, total electromechanical systole (measure of inotropic activity), preejection period, QTc interval, plasma potassium levels, and forced expiratory volume in 1 second were made 5 minutes after each dose and again at 60 and 75 minutes. There were no differences in the bronchodilating effect between the beta-agonists. However, both fenoterol and isoproterenol resulted in greater positive inotropic stimulation than did albuterol, and fenoterol caused a greater fall in plasma potassium levels than did the other beta-agonists.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976051     DOI: 10.1038/clpt.1990.152

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Dose-response of inhaled drugs in asthma. An update.

Authors:  D J Clark; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

2.  Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients.

Authors:  B J Lipworth; D M Newnham; R A Clark; D P Dhillon; J H Winter; D G McDevitt
Journal:  Thorax       Date:  1995-01       Impact factor: 9.139

3.  Effect of beta 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease.

Authors:  C T Yang; H C Lin; M C Lin; C H Wang; C H Lee; H P Kuo
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 4.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects.

Authors:  D M Newnham; N M Wheeldon; B J Lipworth; D G McDevitt
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

Review 6.  Anticholinergic agents for chronic asthma in adults.

Authors:  M Westby; M Benson; P Gibson
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 7.  Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.

Authors:  Preeti Gupta; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 8.  Risks versus benefits of inhaled beta 2-agonists in the management of asthma.

Authors:  B J Lipworth
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

Review 9.  Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?

Authors:  B J Lipworth; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

10.  Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma.

Authors:  K G Bauer; B Kaik; K Sertl; G A Kaik
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.